4D Molecular Therapeutics, Inc.

FDMT

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001650648

SEC filings (opens in a new tab)

In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025 All holders in Q2 2025

13F holders of FDMT: Q2 2025 compared with Q3 2025
Measure	Q2 2025	Of which not filed for Q3 2025	Q3 2025	Change
Holders	121	1	134	+14
Shares	40.4M	54.2K	39.5M	−795.4K (−2.0%)
Value	$149.9M	$201.2K	$343.2M	+$193.5M (+129.3%)

1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (32)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to FDMT in Q3 2025
Institution	Shares	Value	% of portfolio
Parkman Healthcare Partners LLC	200,000	$1.74M	0.19%
Schonfeld Strategic Advisors LLC	179,075	$1.56M	0.01%
Adage Capital Partners GP, L.L.C.	175,000	$1.52M	0.00%
Wellington Management Group LLP	135,470	$1.18M	0.00%
Trexquant Investment LP	81,354	$707.0K	0.01%
Panagora Asset Management Inc	46,979	$408.2K	0.00%
Creative Planning	37,710	$327.7K	0.00%
Quantinno Capital Management LP	35,447	$308.0K	0.00%
STRS Ohio	25,100	$218.1K	0.00%
Capstone Investment Advisors, LLC	22,917	$199.1K	0.00%
ADAR1 Capital Management, LLC	16,712	$145.2K	0.01%
Brevan Howard Capital Management LP	16,400	$142.5K	0.00%
Ballentine Partners, LLC	16,359	$142.2K	0.00%
Quest Partners LLC	15,295	$132.9K	0.01%
Axq Capital, LP	12,879	$111.9K	0.04%
Impact Partnership Wealth, LLC	11,078	$96.3K	0.01%
Inscription Capital, LLC	10,783	$93.7K	0.01%
Martingale Asset Management L P	10,472	$91.0K	0.00%
Abich Financial Wealth Management LLC	9,214	$80.1K	0.03%
SRS Capital Advisors, Inc.	6,038	$52.5K	0.00%
Wexford Capital LP	4,676	$40.6K	0.01%
California State Teachers Retirement System	2,501	$21.7K	0.00%
Global Retirement Partners, LLC	1,500	$13.0K	0.00%
Versant Capital Management, Inc	615	$5.34K	0.00%
GWM Advisors LLC	212	$1.84K	0.00%
Rockefeller Capital Management L.P.	125	$1.09K	0.00%
Marshall & Sterling Wealth Advisors Inc.	100	$869	0.00%
Quadrant Capital Group LLC	95	$826	0.00%
US Bancorp	57	$495	0.00%
True Wealth Design, LLC	54	$470	0.00%
Advisory Services Network, LLC	8	$70	0.00%
Summit Wealth Group LLC	13,204	–	–

Sold out (18)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of FDMT in Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Citadel Advisors LLC	192,239	$713.2K
Gsa Capital Partners LLP	117,719	$437.0K
Redmile Group, LLC	112,168	$416.1K
HRT Financial LP	43,903	$162.0K
Engineers Gate Manager LP	24,015	$89.1K
State of Wisconsin Investment Board	19,798	$73.5K
SG Americas Securities, LLC	17,193	$64.0K
Dynamic Technology Lab Private Ltd	16,369	$61.0K
Voya Investment Management LLC	12,797	$47.5K
Virtu Financial LLC	12,648	$47.0K
Velan Capital Investment Management LP	12,000	$44.5K
Quadrature Capital Ltd	11,257	$41.8K
State Board of Administration of Florida Retirement System	11,187	$41.5K
Meeder Asset Management Inc	5,923	$22.0K
Highline Wealth Partners LLC	3,000	$11.1K
Clear Street Markets LLC	977	$3.63K
Caitong International Asset Management Co., Ltd	546	$2.03K
Fifth Third Bancorp	110	$408

Not filed for Q3 2025 yet (1)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding FDMT in Q2 2025 that haven't filed for Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Norges Bank	54,219	$201.2K